Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2014

01-09-2014 | Editorial

Gut Microbial Translocation in the Pathogenesis of Systemic Inflammation in Patients with End-Stage Renal Disease

Author: Nosratola D. Vaziri

Published in: Digestive Diseases and Sciences | Issue 9/2014

Login to get access

Excerpt

Chronic kidney disease (CKD) accelerates cardiovascular disease, increases the incidence and severity of microbial infections, anemia, cachexia and numerous other morbidities that shorten the life span and greatly impair the quality of patients’ lives. These abnormalities are associated with and are largely mediated by systemic inflammation and oxidative stress, common features of CKD [1], which have been attributed to numerous factors [2]. The severity of CKD-associated systemic inflammation correlates directly with the magnitude of endotoxemia in the absence of clinically detectable infection [3]. Although presence of endotoxin in the blood of ESRD patients was attributed to dialysate contamination, its presence in patients who do not receive dialysis treatment and in animals with experimental renal failure supports its endogenous origin, the most likely source being the gastrointestinal tract, home to a huge microbial community. This assumption is supported by several studies which have reported the presence of gut bacterial DNA fragments in the blood of CKD patients maintained on hemodialysis [4] and in CKD patients who did not receive dialysis treatment [5]. Moreover, colonic bacterial DNA has been detected in the mesenteric lymph nodes, blood, liver and spleen of animals with experimental CKD [6]. …
Literature
1.
go back to reference Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–668.PubMedCrossRef Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–668.PubMedCrossRef
2.
go back to reference Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83:1029–1041.PubMedCentralPubMedCrossRef Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83:1029–1041.PubMedCentralPubMedCrossRef
3.
go back to reference Feroze U, Kalantar-Zadeh K, Sterling KA, et al. Raj DS: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012;22:317–326.PubMedCentralPubMedCrossRef Feroze U, Kalantar-Zadeh K, Sterling KA, et al. Raj DS: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012;22:317–326.PubMedCentralPubMedCrossRef
4.
go back to reference Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:379–385.PubMedCentralPubMedCrossRef Bossola M, Sanguinetti M, Scribano D, et al. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:379–385.PubMedCentralPubMedCrossRef
5.
go back to reference Wang F, Jiang H, Shi K, et al. Gut bacterial translocation is associated with micro-inflammation in end-stage renal disease patients[J]. Nephrology (Carlton). 2012;17:733–738.CrossRef Wang F, Jiang H, Shi K, et al. Gut bacterial translocation is associated with micro-inflammation in end-stage renal disease patients[J]. Nephrology (Carlton). 2012;17:733–738.CrossRef
6.
go back to reference Wang F, Zhang P, Jiang H, Cheng S. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci. 2012;57:2856–2862.PubMedCrossRef Wang F, Zhang P, Jiang H, Cheng S. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci. 2012;57:2856–2862.PubMedCrossRef
7.
go back to reference de Almeida DJ, de Aguilar-Nascimento JE, Nascimento M, et al. Bacterial translocation in experimental uremia. Urol Res. 2004;32:266–270.CrossRef de Almeida DJ, de Aguilar-Nascimento JE, Nascimento M, et al. Bacterial translocation in experimental uremia. Urol Res. 2004;32:266–270.CrossRef
8.
go back to reference Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine—a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21:587–592.PubMedCentralPubMedCrossRef Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine—a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21:587–592.PubMedCentralPubMedCrossRef
9.
go back to reference Vaziri ND, Yuan J, Rahimi A, et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transpl. 2012;27:2686–2693.CrossRef Vaziri ND, Yuan J, Rahimi A, et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transpl. 2012;27:2686–2693.CrossRef
10.
go back to reference Vaziri ND, Yuan J, Nazertehrani S, et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38:99–103.PubMedCrossRef Vaziri ND, Yuan J, Nazertehrani S, et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38:99–103.PubMedCrossRef
11.
go back to reference Vaziri ND, Goshtasbi N, Yuan J, et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36:438–443.PubMedCentralPubMedCrossRef Vaziri ND, Goshtasbi N, Yuan J, et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012;36:438–443.PubMedCentralPubMedCrossRef
12.
go back to reference Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2012;37:1–6.PubMedCentralPubMedCrossRef Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2012;37:1–6.PubMedCentralPubMedCrossRef
13.
go back to reference Vaziri ND, Yuan J, Khazaeli M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 2013;37:518–525.PubMedCentralPubMedCrossRef Vaziri ND, Yuan J, Khazaeli M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 2013;37:518–525.PubMedCentralPubMedCrossRef
14.
go back to reference Vaziri ND, Wong J, Pahl MV, et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int. 2013;83:308–315.PubMedCrossRef Vaziri ND, Wong J, Pahl MV, et al. Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int. 2013;83:308–315.PubMedCrossRef
15.
go back to reference Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol. 2014;39:230–237.PubMedCrossRef Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol. 2014;39:230–237.PubMedCrossRef
17.
go back to reference Rossi UGL, Petrocelli F, Seitun S, Ferro C. Nonconclusive mesenteric ischemia in a dialysis patient with extensive vascular calcification. Am J Kidney Dis. 2012;60:843–846.PubMedCrossRef Rossi UGL, Petrocelli F, Seitun S, Ferro C. Nonconclusive mesenteric ischemia in a dialysis patient with extensive vascular calcification. Am J Kidney Dis. 2012;60:843–846.PubMedCrossRef
18.
go back to reference Gerson LB. The presence of hemodialysis has been associated with GI hemorrhage, likely owing to intermittent usage of heparin for dialysis treatments and the presence of uremia-induced platelet dysfunction. Am J Med. 1985;79:552–559.CrossRef Gerson LB. The presence of hemodialysis has been associated with GI hemorrhage, likely owing to intermittent usage of heparin for dialysis treatments and the presence of uremia-induced platelet dysfunction. Am J Med. 1985;79:552–559.CrossRef
Metadata
Title
Gut Microbial Translocation in the Pathogenesis of Systemic Inflammation in Patients with End-Stage Renal Disease
Author
Nosratola D. Vaziri
Publication date
01-09-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3287-z

Other articles of this Issue 9/2014

Digestive Diseases and Sciences 9/2014 Go to the issue

GRG Profiles and Perspectives

GRG Profiles: Professor Ignazio Marino

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine